Table 1.
Baseline characteristics and measurements
| PTSD | Controls | ||
|---|---|---|---|
| (n = 14) | (n = 14) | P value | |
| Age | 34.4 ± 1.7 | 32.2 ± 1.5 | 0.331 |
| Sex (male/female) | 12/2 | 13/1 | 1.0 |
| Race (black/white) | 10/4 | 12/2 | 0.645 |
| Weight (kg) | 93.8 ± 6.2 | 88.1 ± 4.8 | 0.416 |
| BMI (kg m–2) | 30.1 ± 1.6 | 28.4 ± 1.2 | 0.393 |
| Depression (yes/no) | 2/12 | 2/12 | 1.0 |
| SSRI (yes/no) | 4/10 | 2/12 | 0.645 |
| SBP (mmHg) | 133 ± 3 | 128 ± 4 | 0.351 |
| DBP (mmHg) | 81 ± 2 | 77 ± 4 | 0.389 |
| MAP (mmHg) | 99 ± 3 | 95 ± 4 | 0.451 |
| HR (beats min–1) | 68 ± 4 | 62 ± 2 | 0.267 |
| MSNA (bursts min–1) | 19.8 ± 1.3 | 19.9 ± 2.5 | 0.952 |
| MSNA [bursts (100 heart beats)–1] | 32.2 ± 3.1 | 32.7 ± 4.2 | 0.929 |
| MSNA (AU min–1) | 9934 ± 1022 | 10950 ± 1648 | 0.605 |
| CAPS‐IV score | 81 ± 9 | 39 ± 3 | 0.001 |
Baseline measurements of body mass index (BMI), SBP, DBP, HR and MSNA calculated as burst frequency (bursts min–1) and burst incidence were compared between PTSD and Controls without PTSD. SSRI, serotonin reuptake inhibitor. CAPS‐IV was used to confirm PTSD diagnosis in subjects and exclude PTSD in Controls. Values are the mean ± SE. * P < 0.05 was considered statistically significant.